Focused on developing treatments for food allergies, the France-based biotechnology firm is best known for its Viaskin platform, an epicutaneous immunotherapy patch designed to deliver allergens through the skin to build immune tolerance. Its lead programs have targeted peanut and other common food ...
No congressional trades have been disclosed for DBV Technologies S.A. (DBVT) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.